The purpose of the present work was to identify the catalytic activity of AGXT2L1 and AGXT2L2, two closely related, putative
pyridoxal-phosphate-dependent
enzymes encoded by vertebrate genomes. The existence of bacterial homologues (40-50% identity with AGXT2L1 and AGXT2L2) forming bi- or tri-functional
proteins with a putative
kinase belonging to the family of
aminoglycoside phosphotransferases suggested that AGXT2L1 and AGXT2L2 acted on phosphorylated and aminated compounds. Vertebrate genomes were found to encode a homologue (AGPHD1) of these putative bacterial
kinases, which was therefore likely to phosphorylate an amino compound bearing a
hydroxyl group. These and other considerations led us to hypothesize that AGPHD1 corresponded to 5-hydroxy-L-lysine
kinase and that AGXT2L1 and AGXT2L2 catalyzed the
pyridoxal-phosphate-dependent breakdown of
phosphoethanolamine and 5-phosphohydroxy-L-lysine. The three recombinant human
proteins were produced and purified to homogeneity. AGPHD1 was indeed found to catalyze the
GTP-dependent phosphorylation of 5-hydroxy-L-lysine. The phosphorylation product made by this
enzyme was metabolized by AGXT2L2, which converted it to
ammonia,
inorganic phosphate, and
2-aminoadipate semialdehyde. AGXT2L1 catalyzed a similar reaction on
phosphoethanolamine, converting it to
ammonia,
inorganic phosphate, and
acetaldehyde. AGPHD1 and AGXT2L2 are likely to be the mutated
enzymes in 5-hydroxylysinuria and 5-phosphohydroxylysinuria, respectively. The high level of expression of AGXT2L1 in human brain, as well as data in the literature linking AGXT2L1 to
schizophrenia and
bipolar disorders, suggest that these diseases may involve a perturbation of brain
phosphoethanolamine metabolism. AGXT2L1 and AGXT2L2, the first ammoniophospholyases to be identified, belong to a family of
aminotransferases acting on ω-
amines.